Recommendations for dermatologists treating patients with atopic dermatitis during the Covid-19 pandemic: a look into the past for a conscious vaccination management

Hum Vaccin Immunother. 2021 Oct 3;17(10):3268-3275. doi: 10.1080/21645515.2021.1925502. Epub 2021 Jun 25.

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects approximately 20% of children and 10% of adults. The implication of vaccines as a trigger for the de novo onset of AD in children or as a cause of exacerbation in individuals with a history of AD has long been debated. We present a brief review of the literature on AD and traditional vaccinations, proposing in addition the main recommendations for the management of patients with AD undergoing the vaccine against the SARS-COV-2 virus. Live attenuated vaccines seem to be associated with a relapse of AD and/or complications, such as eczema vaccinatum. For non-live vaccines, no adverse events are noted in atopic subjects. Since the Covid-19 vaccine is mRNA or viral vectored vaccine and there are no other currently used vaccines of this type, the same recommendations are applied as for all other non-live vaccines.

Keywords: Atopic dermatitis; covid-19; dermatologist; dermatology; recommendations; vaccination; vaccine.

Publication types

  • Review

MeSH terms

  • Adult
  • COVID-19 Vaccines
  • COVID-19*
  • Child
  • Dermatitis, Atopic* / epidemiology
  • Dermatitis, Atopic* / therapy
  • Dermatologists
  • Humans
  • Pandemics
  • SARS-CoV-2
  • Vaccination

Substances

  • COVID-19 Vaccines